AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06234176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
Study NCT06154928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drinking Warm Water Intervention
Description: Patients in the Warm Water Group (WG) received a warm water drinking intervention post-laparoscopic cholecystectomy. Before intake, the bed head was elevated to 45°C, and gagging and swallowing reflexes were assessed using an Abeslang to touch the oropharynx. Nausea indicated a positive reflex. Two patients with negative reflexes were excluded from WG. To maintain water temperature, individual insulated cups with thermal features were used, preventing infection transmission. Water was boiled in a clinic kettle, cooled to 37-38°C, and given to patients to drink within 15 minutes. Swallowing ability was monitored after the first sip; successful swallowing allowed the patient to continue. Patients were observed for 15 minutes with an aspirator on standby for aspiration risks. No complications occurred during the water drinking process in WG.
Study NCT06497803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led Body Protection Education
Description: Based on BST and Safe Touches education programs and in line with the studies conducted in the literature on children who are not visually impaired, NLBPE was created by the researchers (Akgul et al., 2021; Citak-Tunc et al., 2018; Pulido, 2019; Wurtele, 2007). The program aims to teach visually impaired children how to protect the private parts of their bodies, to distinguish between good and bad touch, to distinguish between good and bad secrets, to say no, scream, and ask for help when necessary. As education tools, dolls and distress whistles were used. In order for children to learn the private parts of their bodies, a doll was used. The practice of Say No, Scream, Run, and Blow Your Whistle While Running in order for the students to protect their body from bad touch was applied by the students one by one firstly, and in groups later.
Study NCT06497803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminder Education Brochure
Description: The brochure was prepared in line with the NLBPE and included what is a good touch and a bad touch, how to distinguish a good touch from a bad touch, examples of good touch and bad touch, and what to do when encountered with a bad touch (Say No, Scream, Run, and Blow Your Whistle While Running). The brochure, the content of which was prepared by the researcher, was translated into Braille Alphabet by a visually impaired teacher working at the school where the research was conducted, before it was distributed to the intervention group members.
Study NCT06327776 — intervention group
Intervention type: OTHER
Intervention: Serum and saliva biomarkers
Description: 2x5mL blood samples and saliva samples will be used to determine the performance of different blood based and saliva biomarkers for determining diagnostic management and prognosis in mTBI patients.
Study NCT06342336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-IT101 Injection
Description: Adoptive transfer of 5x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study NCT05275582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE
Description: Behavioral intervention including~-30 minute meeting alone with behavioral health educator (in person or virtual using VA's VVC system) 4 weeks of optional self monitoring using an app of substance use behavior, mood, other behavioral processes 2 optional 15-minute phone calls with behavioral health educator
Study NCT05880667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Stereotactic Body Radiation
Description: Radiation therapy is given following generation of planning imaging at the time of simulation. A recent development has been diagnostic quality onboard imaging incorporated within radiation treatment machines. The incorporation of onboard imaging into standard practice has allowed the use Stereotactic Body Radiation (SBRT), which is a precise radiation technique that allows safe delivery of ablative radiation doses.~More recently, the development of improved technologies and software have allowed radiation plans to be generated and delivered that are specific to the anatomy of the very moment the patient is being treated. This novel ability to adjust the radiation treatment plan based upon real time imaging is termed adaptive radiation therapy. This study will utilize the novel adaptive radiation therapy technology in a patient population with technically challenging disease to deliver ablative radiation with an appropriately low toxicity rate.
Study NCT05615142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiotherapy
Description: LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 6 Gy/3f with conventional external beam radiation.
Study NCT05615142 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Partial SBRT at dose escalation levels: 10 Gy/1f, 20 Gy/2f, 30 Gy/3f.
Study NCT05615142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: Patients will receive treatment with PD-1 inhibitor (dose as recommended in the instruction manual) every 3 weeks for a maximum of 48 months.
Study NCT04757805 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound to locate the appropriate lumbar interspace to perform spinal anesthesia.
Study NCT04660786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide
Description: local immunosuprresent
Study NCT04660786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: local immunomodulator
Study NCT06091059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound MRI fusion
Description: Fused MRI images with direct ultrasound guidance
Study NCT06454045 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once a day for 14 days.
Study NCT04210999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homebased resistance training
Description: Resistance training at home instructed via a smart phone training app
Study NCT04210999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised heavy slow resistance training
Description: Heavy slow resistance training in the gym instructed by a physiotherapist
Study NCT05707247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: software
Description: The experimental medical device is a prototype software. It is a patient interface.~The device comes in the form of a smartphone with a touch screen
Study NCT05575297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate Sodium
Description: Methotrexate oral administration alone
Study NCT05575297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin Sodium
Description: Co-administration of methotrexate and rifampicin
Study NCT05575297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat Tablets
Description: Co-administration of methotrexate and febuxostat
Study NCT04936685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine
Description: Liquid solution for injection Intramuscular
Study NCT05392647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Description: All eligible patients were given hetrombopag orally at an initial dose of 5 mg once daily after overnight fasting (>8 hours of fasting) and at least 2 hours before a meal . The dose of hetrombopag could be modified on the basis of the platelet count of patients after 2 weeks of administration.
Study NCT05761613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CeraShield Endotracheal Tube
Description: An endotracheal tube coated with with an antimicrobial hydrophilic coating containing ceragenins (CSAs)
Study NCT05761613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube with subglottic secretion drainage
Description: An endotracheal tube with subglottic secretion drainage
Study NCT05051969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Mindfulness-Based Stress Reduction Program
Description: Enrolled participants will participate in a remote-delivered (online with audio and video) Mindfulness-Based Stress Reduction (MBSR) program. MBSR is a well established behavioral health intervention consisting of 10-sessions lasting 2.5 hours, with one session lasting 7.5 hours in an all-day retreat format over a 2-month period.
Study NCT04331093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210+Apatinib
Description: Drug: SHR-1210 SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg~Drug: Apatinib Apatinib tablet will be administered orally,once daily until progression
Study NCT06323213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 610
Description: 610 subcutaneously injection.
Study NCT06323213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously injection.
Study NCT04969588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microsoft Azure Kinect Developer Kit
Description: 3D images and 3D joint coordinates are obtained.
Study NCT04969588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analyzer
Description: Fat mass, fat-free mass and percentage body fat in total body and body segments are estimated.
Study NCT04969588 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dual Energy X-ray Absorptiometry
Description: Skeletal length and body composition are estimated.
Study NCT04739592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium vitamin D3 tablets
Description: once per week for one year
Study NCT04739592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once per week for one year
Study NCT05274529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological health and flexibility
Description: A remote coaching programme concentrating on psychological health and flexibility
Study NCT05274529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work ability
Description: A remote coaching programme concentrating on work ability
Study NCT05274529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep and recovery
Description: A remote coaching programme concentrating on sleep and recovery
Study NCT05274529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle
Description: A remote coaching programme concentrating on healthy lifestyle
Study NCT05274529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No coaching
Description: Participants also have the option to choose no coaching for the coming 3 month period.
Study NCT04591171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: n-of-1 trial guided clinical decision making
Description: The n-of-1 trial will, on the level of the individual patient, test which treatment strategy produces superior blood pressure reduction without unacceptable side effects. After discussion with the patient/caregiver dyad to identify whether they have specific concerns about particular medications, the nephrologist (clinician) will decide which two drugs and dosages will be tested in the n-of-1 trial (the protocol does not determine drug or dose). The two drugs chosen by the clinician will be assessed at clinician-selected dosing in a randomized treatment order (e.g., ABAB) for two weeks per treatment period and two treatment periods per drug.
Study NCT05492851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zilretta
Description: Intra-articular injection to treat knee osteoarthritis
Study NCT05492851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One 48 MG in 6 ML Prefilled Syringe
Description: Intra-articular injection to treat knee osteoarthritis
Study NCT05492851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc 88 MG Per 4 ML Prefilled Syringe
Description: Intra-articular injection to treat knee osteoarthritis
Study NCT05733182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3000K Reading lamp
Description: Reading lamp with custom-made circuitry to emit light of 3000K colour temperature
Study NCT05733182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4500K Reading lamp
Description: Reading lamp with custom-made circuitry to emit light of 4500K colour temperature
Study NCT04711343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2306
Description: 150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
Study NCT04711343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosentyx (US-licensed)
Description: 150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
Study NCT04711343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosentyx (EU-licensed)
Description: 150mg/1 ml; single dose；prefilled syringe; subcutaneous injection
Study NCT04745871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Description: The PSMA PET/CT will be performed on an outpatient in the nuclear medicine department of the Brest University Hospital (CHRU). For this exam, the administration of 2-4 MBq/kg of 68Ga-HBED-CC-PSMA will be performed to patient by a single intravenous injection.
Study NCT05162430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg, kg, 0.5mg/kg Propofol was injected to five groups of P1, P2, P3, P4 and P5, respectively, and 5mg dexamethasone sodium phosphate was given to groups P1, P2, P3, P4, P5 and D1 after 30s
Study NCT05403840 — intervention group
Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: Surgical mitral valve repair or replacement
Study NCT05403840 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter mitral valve intervention
Description: Transcatheter mitral valve repair or replacement
Study NCT05481827 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GT005
Description: GT005 is a gene therapy for GA and is a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I. GT005 was administered to all participants in an antecedent study prior to enrollment in ORACLE and GT005 is not administered in the ORACLE study.
Study NCT06121531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Contact Lens
Description: Vision Correction
Study NCT06121531 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens
Description: Vision Correction
Study NCT04230772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Orifice Specimen Extraction Surgery
Description: In the experimental group, patients will be performed robotic colorectal resection with natural orifice specimen extraction.
Study NCT04230772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Robotic-assisted Surgery
Description: In the active comparator group, patients will be performed traditional robotic-assisted colorectal resection.
Study NCT05733182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6500K Reading lamp
Description: Reading lamp with custom-made circuitry to emit light of 6500K colour temperature
Study NCT04945564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen therapy and physical therapy
Description: Patients receive oxygen therapy and physical therapy
Study NCT04945564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: Patients receive oxygen therapy
Study NCT05588934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Gum
Description: Commercially available caffeinated gum that contains 100mg of caffeine per piece of gum.
Study NCT05588934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Gum
Description: Commercially available non-caffeinated gum.
Study NCT05588934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gum
Description: Commercially available non-caffeinated gum.
Study NCT04497532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet as suited for gestational diabetes mellitus
Description: Diet that consists of complex carbohydrates, and a regimen that includes 6 meals per day, as tailored gor gestational diabetes.
Study NCT05472571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forest bathing
Description: The intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. Each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses.
Study NCT05233215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW (Glioma Specialists Reaching Out With Support) Support Program
Description: Follow-up survivorship care plan for patients and caregivers
Study NCT05946694 — intervention group
Intervention type: OTHER
Intervention: intubation in manikin
Description: Evaluation of 3 videolaryngoscopes under simulated out-of-hospital conditions by people without clinical experience on a manikin model
Study NCT05857592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adaptive functioning self-report questionnaire
Description: A self-report questionnaire for assessing level of adaptive functioning
Study NCT05857592 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Adaptive functioning self-report questionnaire - adapted
Description: A self-report questionnaire for assessing level of adaptive functioning, adapted to the communication level of the participant
Study NCT06237777 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SKG0106 intravitreal injection dose level 1, 2 or 3
Description: SKG0106 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.
Study NCT05397847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Rational Drug Use in Elderly Individuals~1. Training: Through home visits, an average of 30 minutes of training will be given to elderly individuals (drugs, rational drug use, the importance of rational drug use, and what the elderly should do for rational drug use). Question-answer method and visual materials will be used in the training.~2. Training: An average of 20 minutes of training will be given, including a brief repetition of the topics covered in the first training, via a home visit. Visual materials will be used in the training.
Study NCT05397847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rational Drug Use Guide
Description: At the end of the first training, a rational drug use guide will be given to elderly individuals, including the topics explained.
Study NCT05695963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: RLS history, RLS treatments, and International Restless Legs Syndrome Rating Scale (IRLSRS) will be recorded
Study NCT05695963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auto-questionnaires
Description: To evaluate sleep quality, daytime somnolence and mood disorders (Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and Hospital Anxiety and Depression Scale (HADS)).
Study NCT05695963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Description: 4 electronic interviews administred per day during 14 days by a study-dedicated Android OS smartphone
Study NCT05695963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activity-rest cycle
Description: To further investigate the mutual influence of sleep quality on RLS symptoms and mood, the activity-rest cycle will be monitored by wearable actigraph to be placed on the non-dominant wrist during a period of 13 days and 14 nights.
Study NCT06236048 — intervention group
Intervention type: PROCEDURE
Intervention: MRI scan
Description: 7 Tesla MRI scan
Study NCT06236048 — intervention group
Intervention type: PROCEDURE
Intervention: PET-MR scan
Description: 18F-fluorodeoxyglucose PET-MR scan
Study NCT05397847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medicine Box
Description: Elderly individuals will be given a medicine box large enough to be carried in the pocket when appropriate, so that the elderly people do not forget their medicines and use them regularly, with a 7-day medicine compartment that organizes their medicines and a daily (morning, noon, evening and night) medicine box.
Study NCT05397847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: After the training, counseling services will be given to elderly individuals regarding rational drug use. Within the scope of the counseling service, it will be ensured that the drugs used by the elderly person are regulated and their questions about rational drug use will be answered.